The Dbp5 cycle at the nuclear pore complex during mRNA export I: dbp5 mutants with defects in RNA binding and ATP hydrolysis define key steps for Nup159 and Gle1

Christine A. Hodge,1 Elizabeth J. Tran,2,7 Kristen N. Noble,2,6 Abel R. Alcazar-Roman,2,8 Rakefet Ben-Yishay,3,4 John J. Scarcelli,1,9 Andrew W. Folkmann,2 Yaron Shav-Tal,3,4 Susan R. Wente,2 and Charles N. Cole1,5,10

1Department of Biochemistry, Dartmouth Medical School, Hanover, New Hampshire 03755, USA; 2Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA; 3The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan 52900, Israel; 4Institute of Nanotechnology, Bar-Ilan University, Ramat Gan 52900, Israel; 5Department of Genetics, Dartmouth Medical School, Hanover, New Hampshire 03755, USA; 6Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee 27208, USA

Nuclear export of messenger RNA (mRNA) occurs by translocation of mRNA/protein complexes (mRNPs) through nuclear pore complexes (NPCs). The DEAD-box protein Dbp5 mediates export by triggering removal of mRNP proteins in a spatially controlled manner. This requires Dbp5 interaction with Nup159 in NPC cytoplasmic filaments and activation of Dbp5's ATPase activity by Gle1 bound to inositol hexakisphosphate (IP6). However, the precise sequence of events within this mechanism has not been fully defined. Here we analyze dbp5 mutants that alter ATP binding, ATP hydrolysis, or RNA binding. We found that ATP binding and hydrolysis are required for efficient Dbp5 association with NPCs. Interestingly, mutants defective for RNA binding are dominant-negative (DN) for mRNA export in yeast and human cells. We show that the DN phenotype stems from competition with wild-type Dbp5 for Gle1 at NPCs. The Dbp5–Gle1 interaction is limiting for export and, importantly, can be independent of Nup159. Fluorescence recovery after photobleaching experiments in yeast show a very dynamic association between Dbp5 and NPCs, averaging <1 sec, similar to reported NPC translocation rates for mRNPs. This work reveals critical steps in the Gle1-IP6/Dbp5/Nup159 cycle, and suggests that the number of remodeling events mediated by a single Dbp5 is limited.

[Keywords: nucleocytoplasmic transport; DEAD-box proteins; nuclear pore complex; FRAP; dominant-negative mutants]

Supplemental material is available for this article.

Received February 14, 2011; revised version accepted April 1, 2011.
are eight filaments that extend into the cytoplasm ([cytoplasmic filaments, CFs], and a basket-like structure that extends into the nucleus. Nucleoporins [nups] that comprise these asymmetric structures are found exclusively on one side of the NPC. mRNA export involves a complex set of interactions that occur on CFs.

A key event during mRNA export is dissociation of protein components from mRNPs, which is thought to contribute to export directionality. This remodeling is mediated by Dbp5 [Lund and Guthrie 2005; Tran et al. 2007], a highly conserved member of the DEAD-box protein [DBP] family of related ATPases [>20 in both yeast and metazoan cells] [for review, see Cordin et al. 2006; Linder 2008]. Many DBPs are able to denature short double-stranded regions of RNA in vitro, and some can remodel mRNA-protein complexes by removing bound proteins [Tran et al. 2007; for review, see Jankowsky 2011].

Dbp5 is the DBP that plays a central role in mRNA export. It was identified initially through a genetic screen in Saccharomyces cerevisiae aimed at identifying mRNA export factors and was called Rat8 [ribonucleic acid transport] [Snay-Hodge et al. 1998]. In yeast cells carrying temperature-sensitive [ts] alleles of RAT7/DBP5, poly[A]+ RNA accumulates rapidly in nuclei upon a shift to 37° C. Dbp5 interacts with two proteins located at or near the NPC CFs: Nup159 and Gle1 [Hodge et al. 1999; Schmitt et al. 1999; Strahm et al. 1999]. This has led to working models wherein Dbp5 is proposed to function late during mRNA export by catalyzing the remodeling of mRNPs [Cole et al. 2002; Cole and Scarcelli 2006; Tran and Wente 2006; Stewart 2007, 2010].

Gle1 acts in concert with the soluble phosphoinositide inositol hexakisphosphate (IP6) to stimulate ATP hydrolysis by Dbp5 at the NPC, precisely at the location where mRNPs exit the NPC channel [York et al. 1999; Alcazar-Roman et al. 2006; Weirich et al. 2006; Wente and Rout 2010]. This converts Dbp5–ATP to Dbp5–ADP, thereby driving dissociation of protein from the mRNP [Tran et al. 2007; Noble et al. 2011]. There is evidence that the mRNA export receptor Mex67 and the RNA-binding protein Nab2, both of which accompany the mRNP through NPCs, are removed from mRNPs by Dbp5 acting at the CFs [Lund and Guthrie 2005; Tran et al. 2007]. Nab2 may function as an adapter for Mex67 [Carmody et al. 2010; Iglesias et al. 2010], which mediates the interaction of mRNPs with NPCs [Segrel et al. 1997; Strawn et al. 2001; Terry and Wente 2007]. Thus, removal of Nab2 by Dbp5 would promote release of the mRNP into the cytoplasm. Overall, mRNA export is mediated by the interaction of Dbp5 with Nup159, Gle1, ATP, ADP, and mRNP.

Although Dbp5 binds to the N-terminal domain [NTD] of Nup159, this interaction is not essential [Del Priore et al. 1997]. Yeast strains harboring the nup159ΔN or nup159ΔE-VI allele, encoding Nup159 lacking or mutated in its Dbp5-binding site, display severe mRNA export and temperature-sensitive growth defects [Hodge et al. 1999; Weirich et al. 2004]. However, overexpression of DBP5 completely suppresses these defects.

To gain a mechanistic understanding of the role Dbp5 plays in the mRNA export process, we set out to define the order of Dbp5-dependent events at the NPC. To this end, we used DBP5 point mutants defective for ATP binding, ATP hydrolysis, and RNA binding. The two unable to bind RNA are also dominant-negative [DN]. By investigating both the mutant in vivo phenotypes and the biochemical properties of the altered proteins in vitro, critical steps in the Dbp5 cycle during export were defined and their order was revealed. In addition, we examined the in vivo dynamics of mutant and wild-type Dbp5 in yeast and human cells. Fluorescence recovery after photobleaching [FRAP] experiments in yeast reveal that Dbp5 has a very dynamic association with NPCs, while live-cell analysis of mRNP trafficking in human cells showed that the R372G mutant of hDbp5, analogous to the DN yeast mutant R369G, also has a DN effect on mRNA export and causes accumulation of single mRNPs at the nuclear periphery. We found that ATP binding and ATP hydrolysis are required for efficient association of Dbp5 with NPCs. Furthermore, RNA binding to Dbp5 is required for efficient release of Dbp5 from Gle1, but is independent from docking of Dbp5 at Nup159. From this we propose a model wherein Dbp5 interacts with Nup159 [Nup214 in human cells] and is then transferred to Gle1. Gle1-IP6 activates Dbp5 ATPase activity and positions it to remodel mRNPs during NPC exit. Interaction with Gle1 is limiting for mRNA export and can be independent of Nup159. Analysis of the R369G mutant suggests that its dominant phenotype reflects competition for Gle1. Furthermore, once bound to Gle1 at the NPC, R369G appears to occupy these sites longer than wild-type Dbp5 because it cannot bind mRNPs. In a companion study [Noble et al. 2011], we show that Nup159 catalyzes dissociation of ADP from Dbp5, and present a model wherein we propose that an individual Dbp5 polypeptide is able to mediate more than one round of mRNP remodeling through cyclical interactions with its binding partners.

Results

Isolation and characterization of S. cerevisiae DBP5 mutants affecting ATP binding, ATP hydrolysis, and RNA binding

During mRNA export, Dbp5 has multiple binding partners: Nup159, Gle1, RNA [e.g., mRNP], ATP, and ADP [resulting from hydrolysis of ATP]. To determine the order of events involving Dbp5 at the NPC, we constructed DBP5 mutants affecting DBP motifs I [K144Q], II [E240Q], and VI [R426Q] [Fig. 1A]. These residues were selected based on prior studies of human Dbp5 and other DBPs. Motifs I [AxxGxGKT] and II [DExD] are the Walker A and B boxes present in all DBPs and most NTPases [for review, see Jankowsky 2011]. In other DBPs, motif I is required for ATP binding, motifs I and II are required for ATPase activity, and motif VI [HHRGRRGxR] plays an important role in both ATPase activity and RNA binding [Pause et al. 1994; Linder 2008]. Expressed as the only form of Dbp5, none of these mutants were viable [Supplemental Fig. S1].
Each mutant was also placed under control of the \textit{GAL1} promoter in wild-type cells to permit induced high-level expression by growth in galactose (gal) medium. Figure 1B compares growth on dextrose (dex) and gal plates for wild-type cells carrying each of these \textit{GAL1} plasmids. The K144Q and E240Q mutants were not DN. In contrast, expression of R426Q inhibited growth. From a genetic screen to identify DN mutants of Dbp5, we identified R369G as a strong DN allele (also shown in Fig. 1B). Next, we examined the effect of these alleles on mRNA export in the presence of wild-type Dbp5. Consistent with their being recessive lethal alleles, coexpression of K144Q or E240Q with wild-type Dbp5 had no effect, whereas R369G and R426Q induction led to nuclear accumulation of poly(A)$^+$ RNA (Fig. 1C). The export defect was detected within 60 min of a shift from raffinose (raf) to 2% gal medium, and was seen in all cells within 3 h. These defects are not due to differences in protein levels, as all Dbp5 variants accumulated with approximately the same kinetics and to much higher levels than wild-type Dbp5-GFP expressed from the \textit{DBP5} locus (Fig. 1D). The results suggest that the DN phenotypes reflect defects in the Dbp5 enzymatic cycle during mRNA export.

GFP-tagged versions of the altered proteins were used to determine subcellular localization. GFP fusions to R369G and R426Q retained the DN phenotypes of the untagged forms, although with some reduction in the strength of growth inhibition [data not shown]. Wild-type Dbp5-GFP, R369G-GFP, and R426Q-GFP were readily detected at the nuclear rim [Fig. 2A], reflecting NPC association. In contrast, K144Q-GFP and E240Q-GFP were predominantly cytoplasmic with little or no NE signal detected [Fig. 2A]. To further test whether the K144Q or E240Q proteins had any ability to associate with NPCs, we deleted genomic \textit{DBP5} and expressed wild-type Dbp5 from a gal-inducible promoter. Following depletion of wild-type Dbp5 by shifting cells from gal to dex, E240Q-GFP, but not K144Q-GFP, became detectable at NPCs, but the signal was considerably weaker than that for wild-type Dbp5-GFP [Fig. 2B]. Western blots showing depletion of wild-type Dbp5 are in Supplemental Figure S2. Taken together, the contrasting effects on NPC

---

**Figure 1.** Effect of overexpressed wild-type and altered Dbp5 proteins on growth and mRNA export. [A] Organization of Dbp5, location of conserved DBP motifs, and location of mutations shown. [B] Effect of inducing expression of high levels of wild-type or altered Dbp5 proteins on yeast cell growth. Serial dilutions of wild-type yeast cells containing \textit{GAL1} plasmids encoding wild-type or altered Dbp5 were plated on plates containing dex or gal and incubated for 5 d at 30°C. [C] Coding regions for wild-type and altered Dbp5 were placed under control of the \textit{GAL1} promoter. Expression of wild-type or altered proteins was induced by transfer of cells from 2% raf to 2% gal and poly(A)$^+$ RNA distribution detected by fluorescent in situ hybridization (FISH). [D] Western blot for wild-type and altered Dbp5 proteins. Cells were grown overnight in raf and then incubated in medium containing either 2% dex or 2% gal for indicated times. All cells express Dbp5-GFP from the genomic \textit{DBP5} locus, with its position also shown.
association indicated distinct defects in the mRNA export mechanism for the K144Q and E240Q versus the DN R369G and R426Q proteins.

A DN phenotype generally reflects competition between wild-type and DN mutant proteins for limiting binding sites or substrate. We tested whether overexpression of wild-type Dbp5 could suppress the DN R369G phenotype. Using cells expressing wild-type Dbp5 from its genomic locus and either the R369G or both R369G and wild-type Dbp5 under control of the GAL1 promoter, we found that increasing the ratio of wild-type Dbp5 to R369G reduced growth inhibition by R369G [Fig. 2B]. Western blots indicate that R426Q and wild-type Dbp5 were highly expressed. In the experiments in Figure 2, both wild-type Dbp5 and R369G were untagged, since tags reduce the functionality of wild-type Dbp5 and the DN phenotypes of R369G. In a parallel experiment, we analyzed expression of tagged constructs (Supplemental Fig. S3) to distinguish genomic Dbp5 from gal-induced Dbp5 and R369G. Tagged wild-type Dbp5 and R369G were each expressed at severalfold the level of Dbp5-GFP produced from its genomic locus (Supplemental Fig. S3). We conclude that R369G inhibition occurs by a competitive mechanism. The most likely limiting components are Dbp5 interaction partners at the NPC: Nup159 and/or Gle1.

**Biochemical properties of defective Dbp5 proteins**

Our previous work demonstrated that ATP hydrolysis by Dbp5 is stimulated by RNA and is further increased by coactivators Gle1 and IP6 [Alcazar-Roman et al. 2006]. To determine whether the altered dbp5 proteins had perturbed biochemical activities, each was expressed in bacteria and purified for in vitro biochemical assays. ATPase assays were conducted in the presence of RNA and either Gle1 or Gle1-IP6, and results were normalized to the activity measured for wild-type Dbp5 [Fig. 3A]. Consistent with alteration of essential motifs needed for ATP binding and hydrolysis, the K144Q, E240Q, and R426Q proteins showed minimal ATPase activity alone, and this activity was not stimulated by Gle1-IP6 [Fig. 3A]. Importantly, the R369G protein retained ATPase activity with ∼60% the wild-type level of Gle1-IP6-dependent ATP hydrolysis [Fig. 3A]. Interestingly, Gle1 addition without IP6 reduced R369G ATPase activity, whereas Gle1 stimulates wild-type Dbp5 even in the absence of IP6 [Fig. 3A]. This suggested that R369G is impacted differently by Gle1.

Next, we performed ATP- and RNA-binding assays to assess substrate and ligand binding. ATP binding was analyzed quantitatively by in vitro UV cross-linking of $^{32}$P-α-ATP (10 nM) to purified protein in the presence or absence of RNA [Fig. 3B]. Substitution of the critical lysine in the Walker A motif (K144Q) abolished ATP binding, which was not restored by addition of RNA [Fig. 3B]. In contrast, the E240Q Walker B mutant enhanced ATP binding to a level ∼2.5 times that of wild-type Dbp5. The R369G and R426Q proteins alone each had reduced ATP binding. We conclude that loss of ATP binding or ATPase activity by Dbp5 is not sufficient to cause a DN growth phenotype, but either mutation results in a loss of function and inhibits NPC binding.

To determine whether the R369G ATPase activity was RNA-dependent, ATPase assays were conducted in the presence of increasing RNA concentrations [Fig. 3C]. Whereas wild-type Dbp5 showed an increase in the initial velocity of ATP hydrolysis at 1 μM RNA, the ATPase activity of R369G was not stimulated at any RNA concentration tested. This suggested that the R369G protein could not bind RNA. To directly examine RNA interaction, filter-binding assays were performed using recombinant proteins and a 5′-$^{32}$P-labeled oligo(A)$_{125}$ RNA molecule. Both the E240Q and K144Q proteins retained the ability to associate with RNA [Fig. 3D]. Consistent with the inability of RNA to stimulate ATP hydrolysis by R369G, R369G had severely reduced ability to bind RNA. R426Q also showed decreased RNA binding. Of note, in the human Dbp5–RNA crystal structure, the residues corresponding by sequence alignment to yeast R369 and R426 are both positioned in the RNA-binding pocket [von Moeller et al. 2009]. While R426 is within a very highly conserved motif shared by all DBPs, the region surrounding R369G is not part of any of the conserved motifs and
shows moderate variation among them. However, comparison of this region of several yeast DBPs and representative DBPs from several other organisms indicates that R369 is the most highly conserved residue in this region (Supplemental Fig. S4). In the structure of a complex between synthetic U10 RNA and human DDX19 (orthologous to yeast Dbp5), the guanidinium group of R372 can form two hydrogen bonds with the phosphodiester backbone of the RNA (Collins et al. 2009).

Because the sites for hDbp5 binding to Nup214 and RNA overlap (von Moeller et al. 2009), we directly tested the altered Dbp5 proteins for in vitro interaction with the NTD of Nup159. In soluble binding assays with purified recombinant proteins (see the Materials and Methods), all interacted similarly to wild type (Fig. 3D). We also assayed for the ability of wild-type Dbp5 versus R369G protein to enhance IP6 binding by Gle1 and found that both were effective to approximately the same extent (Supplemental Fig. S5A). This indicated that R369G binding to Gle1 is not altered compared with wild type. This was verified directly by soluble binding assays with purified recombinant proteins (Supplemental Fig. S5B). Taken together, this suggested that, for R369G, the specific lack of RNA binding underlies its DN inhibition of growth and mRNA export.

**Genetic requirements for the R369G DN growth phenotype**

Because the R369G protein retains the ability to bind and hydrolyze ATP and associates with the NPC in vivo, we hypothesized that the R369G DN phenotype reflects competition between R369G and wild-type Dbp5 for binding Nup159 and/or Gle1. To examine this, we tested the ability of R369G to inhibit growth of strains with mutations in genes encoding Nups located asymmetrically on the cytoplasmic face of the NPC. We used *nup159ΔN*, which lacks its Dbp5-binding site (Del Priore et al. 1997; Hodge et al. 1999; Strahm et al. 1999), and *nup42Δ*. Nup42 directly interacts with Gle1 and is linked to Gle1 function (Murphy and Wente 1996; Hodge et al. 1999, Strahm et al. 1999). We also tested a *gfd1Δ* mutant due to the known functional and physical links between Gfd1 and Dbp5 (Estruch et al. 2005), Gle1 (Suntharalingam et al. 2004), and Nab 2 (Suntharalingam et al. 2004; Zheng et al. 2010). In all cases, the expression of R369G inhibited growth to the same extent as in wild-type cells (Fig. 4A), demonstrating that none of these factors is required for R369G's DN effect.

To further test for links between Dbp5, Gle1, and Nup159, we constructed a set of double mutants wherein *dbp5* contained both the R369G mutation and point mutations that substantially reduce Dbp5’s ability to bind Gle1 (Dossani et al. 2009) or Nup159 (Noble et al. 2011). For mutants affecting the Dbp5–Gle1 interaction, we used *dbp5-E323K* and *dbp5-E473K*. Both are viable, and E473K is temperature-sensitive (Dossani et al. 2009). Strikingly, the R369G/E323K mutant was not DN, and the R369G/E473K mutant was considerably less DN than R369G (Fig. 4B). To probe the Dbp5–Nup159 interaction, we used a R256D/R259D allele encoding a Dbp5 protein that does not interact with Nup159 and is not detected at the nuclear periphery (Noble et al. 2011). The triple R256D/R259D/R369G mutant retained the DN growth phenotype of R369G (Fig. 4B). Finally, we examined the
the R369G protein dramatically reduced the Gle1-IP6-stimulated ATPase activity from R369G or K144Q normalized for the ATPase activity from R369G or K144Q 0.2–5 times the molar Gle1 level (Fig. 5A,B). Assays were decreasing levels of recombinant purified R369G or K144Q at increasing levels of Gle1-IP6 up to a threefold molar excess. In agreement with our predictions, the reduced ATPase activity of wild-type Dbp5 was reversed by addition of increasing Gle1-IP6 levels (Fig. 5C). This activity was not mediated by altering IP6 binding to Gle1, as both wild-type Dbp5 and the R369G protein enhanced IP6 binding to similar extents (Supplemental Fig. S5). This was also consistent with the lack of a requirement for IP6 production [ipk1Δ cells] for R369G to display DN behavior [data not shown]. To investigate the impact of increased Gle1 on R369G in vivo, Gle1 was overexpressed in cells expressing wild-type Dbp5 and R369G. Growth was partially rescued [Fig. 5D]. Overexpression was monitored by Western blotting [Supplemental Fig. S7]. Importantly, although wild-type dbp5-GFP is not readily detectable at the NPCs in nup159ΔN cells, R369G-GFP was still detected at the nuclear periphery [Fig. 5E]. Thus, the DN phenotype of R369G is due to competition for Gle1, leading to impairment of the wild-type Dbp5 ATPase cycle at the NPC. Moreover, this effect is not dependent on Nup159-NTD.

To test this, ATPase assays were conducted as in Figure 5A with Gle1 and ATPase activation. A prediction of this model is that increasing amounts of Gle1 could overcome the DN effect of R369G and restore Dbp5 ATPase activity. To test this, ATPase assays were conducted as in Figure 5A but with increasing levels of Gle1-IP6 (data not shown). To investigate the impact of increased Gle1 on R369G in vivo, Gle1 was overexpressed in cells expressing wild-type Dbp5 and R369G. Growth was partially rescued [Fig. 5D]. Overexpression was monitored by Western blotting [Supplemental Fig. S7]. Importantly, although wild-type dbp5-GFP is not readily detectable at the NPCs in nup159ΔN cells, R369G-GFP was still detected at the nuclear periphery [Fig. 5E]. Thus, the DN phenotype of R369G is due to competition for Gle1, leading to impairment of the wild-type Dbp5 ATPase cycle at the NPC. Moreover, this effect is not dependent on Nup159-NTD.

Increasing Gle1 levels in vitro rescues inhibition of wild-type Dbp5 activity by R369G

To define the mechanistic basis for the Gle1-dependent DN activity of the R369G allele, we conducted a series of in vitro assays. First, we tested whether the R369G protein altered the ability of Gle1-IP6 to activate wild-type Dbp5 ATPase activity. The velocity of ATP hydrolysis for wild-type Dbp5 was measured in the presence of RNA, Gle1-IP6, and increasing levels of recombinant purified R369G or K144Q at 0.2–5 times the molar Gle1 level [Fig. 5A,B]. Assays were normalized for the ATPase activity from R369G or K144Q alone under the same conditions. Strikingly, we found that the R369G protein dramatically reduced the Gle1-IP6-stimulated ATPase activity of wild-type Dbp5 in a concentration-dependent manner [Fig. 5A]. Importantly, the K144Q protein had no effect on wild-type Dbp5 activity [Fig. 5B], consistent with K144Q not being DN.

These results supported our conclusion that the R369G protein is competing with wild-type Dbp5 for association with Gle1 and ATPase activation. A prediction of this model is that increasing amounts of Gle1 could overcome the DN effect of R369G and restore Dbp5 ATPase activity. To test this, ATPase assays were conducted as in Figure 5A but with increasing levels of Gle1-IP6 (up to a threefold molar excess). In agreement with our predictions, the reduced ATPase activity of wild-type Dbp5 was reversed by addition of increasing Gle1-IP6 levels [Fig. 5C]. This activity was not mediated by altering IP6 binding to Gle1, as both wild-type Dbp5 and the R369G protein enhanced IP6 binding to similar extents [Supplemental Fig. S5]. This was also consistent with the lack of a requirement for IP6 production [ipk1Δ cells] for R369G to display DN behavior [data not shown]. To investigate the impact of increased Gle1 on R369G in vivo, Gle1 was overexpressed in cells expressing wild-type Dbp5 and R369G. Growth was partially rescued [Fig. 5D]. Overexpression was monitored by Western blotting [Supplemental Fig. S7]. Importantly, although wild-type dbp5-GFP is not readily detectable at the NPCs in nup159ΔN cells, R369G-GFP was still detected at the nuclear periphery [Fig. 5E]. Thus, the DN phenotype of R369G is due to competition for Gle1, leading to impairment of the wild-type Dbp5 ATPase cycle at the NPC. Moreover, this effect is not dependent on Nup159-NTD.

To further probe for changes in Gle1–Dbp5 interaction mediated by R369G, we measured the level of ATP binding by Dbp5 in the presence of Gle1-IP6. Using an in vitro UV cross-linking assay and recombinant purified proteins, we found that Gle1-IP6 enhanced the level of ATP bound by wild-type Dbp5 by ~3.5-fold [Fig. 5F]. For the R369G protein, addition of Gle1-IP6 increased ~16-fold the amount of bound ATP [Fig. 5F]. Interestingly, the increase in ATP binding for R369G was specific for the presence of Gle1-IP6, as R369G bound little ATP in the absence of Gle1-IP6 [Fig. 3E]. The basal level of ATP binding by the K144Q, E240Q, or R426Q proteins was not altered by addition of Gle1-IP6. This indicated a specific link between Gle1-IP6 action and facilitation of ATP binding to R369G. Overall, we propose that the DN phenotype reflects competition for occupancy of Gle1 at NPCs by R369G, effectively decreasing the capacity of Gle1-IP6 to bind and activate wild-type Dbp5. Furthermore, the data in Figure 5E suggest that R369G may occupy Gle1-binding sites longer than wild-type Dbp5, possibly because it cannot bind RNA and proceed productively through the cycle.

Association of Dbp5 with NPCs is ATP-dependent and highly dynamic

Because the K144Q and E240Q proteins are defective in ATP binding and/or ATPase activity and show little or no in vivo localization to NPCs, we investigated whether the interactions between Dbp5 and NPCs require any particular in vivo nucleotide-bound state. Notably, based on in vitro studies of the human protein [von Moeller et al. 2009], Dbp5 bound to ATP is expected to have the lowest affinity for
Nup159, with Dbp5–ADP and Dbp5–APO having greater affinity. If ATP binding is necessary for efficient NPC association in vivo, cellular depletion of ATP should trigger loss of wild-type Dbp5 from NPCs. Indeed, when cells were treated for 10 min with sodium azide and 2-deoxy-glucose to deplete ATP, wild-type Dbp5-GFP was not detected at the nuclear rim/NPCs (Fig. 6A). In marked contrast, under these conditions, R369G-GFP was detected at the nuclear rim/NPCs. We conclude that, in vivo, NPC association of wild-type Dbp5 is dependent on its nucleotide-bound state, whereas R369G association is independent of ATP.

To examine the dynamics of the Dbp5 interaction with NPCs, we analyzed FRAP in cells expressing Dbp5-GFP from the DBP5 locus. Recovery of fluorescence at NPCs was rapid, with half recovery occurring in ~0.8 sec [Fig. 6B]. One possible concern in these studies is that yeast NPCs are mobile within the NE [Belgareh and Doye 1997; Bucci and Wente 1997]. This contrasts with NPCs of metazoan cells, which are largely immobile due to their interactions with the nuclear lamina [Lenz-Bohme et al. 1997; Liu et al. 2000]. If NPCs with bound Dbp5-GFP were to diffuse within the NE into the bleached area, there would be ambiguity about whether recovery occurred through a Dbp5 dissociation/replacement mechanism or by diffusion within the NE of NPCs to which unbleached Dbp5-GFP was bound. When a small spot on the nuclear rim of cells expressing Nup82-GFP was bleached, we saw no recovery of fluorescence after 30 sec [Fig. 6B], a period substantially longer than the observed period for recovery of Dbp5-GFP after photobleaching. In this experiment, Dbp5-GFP and Nup82-GFP were the only forms of the respective protein present and were expressed from their normal loci. We also compared FRAP of R369G-GFP with Dbp5-GFP, with each expressed from a centromeric plasmid. The Dbp5-GFP fusion is fully functional, as it covers a dbp5-null allele [Hodge et al. 1999]. Tagging R369G with GFP slightly compromised its DN effect on growth (data not shown). Recovery of fluorescence for Dbp5-R369G was also rapid and approximately the same as that of wild-type Dbp5 [Fig. 6C]. This is consistent with Dbp5-R369G functioning as a competitive rather than non-competitive inhibitor of wild-type Dbp5. Although the data in Figure 6, B and C, represent one FRAP analysis for each strain examined, >30 separate analyses were conducted with each, with approximately the same results.

Human Dbp5-R372G inhibits mRNA export in mammalian cells, and mRNPs accumulate at the nuclear periphery

To extend these studies to mammalian cells, we constructed mutants in human Dbp5 that are equivalent to
the yeast mutants R369G (human R372G) and E240Q (human E242Q). After transfection of mammalian U20S cells, the distribution of poly(A)+ mRNA was examined by RNA fluorescence in situ hybridization (FISH). Cells continue to express wild-type Dbp5 from the genomic locus. mRNA is normally detected in both nucleus and cytoplasm, and this was observed for both wild-type hDbp5 (Fig. 7A) and the E242Q mutant (data not shown). In contrast, and consistent with the yeast DN R369G mutant phenotype, mRNAs in cells expressing hDbp5-R372G cells were confined to the nuclear compartment and showed increased accumulation in nuclear speckles (Fig. 7A). This indicates that hDbp5-R372G recapitulates the DN effect on mRNPs export of yeast R369G.

We then analyzed the effect of R372G on the distribution of individual mRNPs in living cells using fluorescence microscopy. To visualize individual mRNPs, we used two constructs employed previously [Mor et al. 2010]: one in which the mRNA is generated without splicing (Mini-Dys), and one that requires splicing (1/2-Mini-Dys+intron mRNA). These mRNAs are engineered to contain multiple sites in their 3’ untranslated regions (UTRs) to which the MS2 phage coat protein can bind. The location of individual mRNPs can be observed by coexpressing a YFP fusion to the MS2 coat protein (YFP-MS2). A normal nucleocyttoplasmic distribution of these mRNPs was seen in untransfected human U20S cells [or in cells transfected with a plasmid encoding hDbp5] (data not shown), whereas the mRNPs were retained in the nucleus in cells expressing hDbp5-R372G (Fig. 7B). To quantify the inhibitory effect of hDbp5-R372G on mRNA export, we counted the number of mRNPs in the nucleus and the cytoplasm (Fig. 7C), confirming the effect of hDbp5-R372G on mRNA export. Imaging individual mRNPs in cells over time has shown that nuclear mRNPs are typically not detected as anchored to the NE but are predominantly dynamic in the nucleoplasm [Supplemental Fig. 8; Mor et al. 2010]. Interestingly, in R372G-expressing cells, an increase in mRNPs anchored to or near the NE was observed (Fig. 7D,E; Supplemental Figs. S8A, S7B; Supplemental Movies S1, S2), while the dynamics of most intranuclear mRNPs were not perturbed [Supplemental Fig. 8A]. This analysis indicates that mRNPs in cells expressing hDbp5-R372G are targeted to the nuclear periphery, yet translocation to the cytoplasm is inhibited. Taken together, these results show that impairment of the interaction between Gle1-IP6 and Dbp5 blocks late mRNA export steps in both yeast and human cells.

Discussion

The studies presented here are directed at defining the sequence of events at NPCs in which Dbp5 participates during mRNA export. During the export cycle, Dbp5 interacts with Nup159, RNA [in the form of mRNP], and Gle1-IP6, as well as with ATP and ADP. By using mutants that impact these interactions, we defined critical steps in the cycle.

First, Dbp5’s ability to bind and hydrolyze ATP is important for its interaction with NPCs, but binding RNA is not. This conclusion is supported by several lines

Figure 6. Association of Dbp5 with NPCs is ATP-dependent and dynamic. (A) Wild-type cells expressing Dbp5-GFP or R369G-GFP were visualized by fluorescence microscopy before and 10 min after addition of sodium azide (10 mM) and 2-deoxy glucose (10 mM). (B) FRAP analysis was performed on wild-type cells expressing Dbp5-GFP or Nup82-GFP from their genomic loci. (C) GFP-tagged proteins (wild-type and R369G) were expressed from centromeric plasmids in wild-type cells under control of the DBP5 promoter. FRAP was performed on the brightest cells. The arrows in B and C indicate the lowest levels to which the signal dropped immediately after photobleaching. The green line in each panel is the bleached sample, and the red line is a control region of the same cell that was not subjected to photobleaching. Each panel in B and C represents a single FRAP analysis. In each case, >30 separate FRAP analyses were performed, with little difference among them and one representative shown.
of evidence from different dbp5 point mutants. The K144Q protein, which is altered in the Walker A box, does not bind ATP [Fig. 3C], is not detected at NPCs even when wild-type Dbp5 is absent [Fig. 2B], and cannot support cell growth [Supplemental Fig. S1]. Consistent with this apparent requirement that Dbp5 bind ATP to allow NPC localization, wild-type Dbp5 is not detected at NPCs when ATP is depleted by treating cells with sodium azide and 2-deoxy glucose (Fig. 6A), agents that together prevent ATP regeneration. Furthermore, the dbp5-E240Q mutant alters the Walker B box and, like K144Q, is a recessive lethal [Supplemental Fig. S1]. E240Q has minimal in vitro ATPase activity that is not stimulated by Gle1-IP6 (Fig. 3A). Like K144Q, the E240Q protein is not present at NPCs in wild-type cells [Fig. 2A], even when overexpressed. In contrast to K144Q, however, a low level of E240Q-GFP at NPCs is observed when wild-type Dbp5 is depleted [Fig. 2B]. This indicates that E240Q has some ability to interact with NPCs, most likely because it can bind ATP, but its interaction with NPCs is inefficient.

We found that the ability to bind RNA is not required for Dbp5 to interact with NPCs. The R369G and R426Q mutants are readily detected at NPCs [Fig. 2A], even though they are defective for RNA binding [Fig. 3D]. Both also have DN effects on growth and mRNA export [Fig. 1]. This epistatic relationship further indicates that the ATP-binding step precedes the RNA-binding step, which is consistent with biochemical analysis of Dbp5–RNA binding: ATP-bound Dbp5 has a greater affinity for RNA than ADP-bound [Weirich et al. 2006; Tran et al. 2007].

Second, mRNA export requires that Dbp5 interact with Gle1; however, as indicated previously, the interaction with Nup159 is not essential. Several nup159 mutants, including nup159ΔN, have been described that have lost the ability to bind Dbp5 but remain viable [Hodge et al. 1999; Weirich et al. 2004]. Similarly, the DN R369G phenotype is not diminished in nup159ΔN cells [Fig. 4A]. Because R369G but not wild-type Dbp5 can be detected at NPCs even when the NTD of Nup159 is absent [Fig. 5E], the signal for wild-type Dbp5 reflects primarily its binding to Nup159, whereas the signal for R369G reflects its occupancy of both Nup159- and Gle1-binding sites. The DN phenotypes reflect competitive inhibition of mRNA export by R369G, since the DN effects were reduced when wild-type Dbp5 or Gle1 was expressed at a high level in cells expressing R369G [Fig. 5D]. This reflects competition by Dbp5 and R369G for Gle1, and demonstrates that the Gle1–Dbp5 interaction is critical and therefore likely a key limiting step in mRNA export.

Third, the inability to bind RNA impedes the cycle at the Gle1 step and inhibits mRNP translocation through NPCs. The DN phenotypes for the yeast R369G and human R372G mutants provide key insights into this step. R369G binds Nup159 and Gle1 and, since it retains ATPase activity, can also be in both the ADP- and ATP-bound states. However, Nup159 binding is not required because a dbp5-R256D/R259D/R369G mutant that likely lacks both Nup159 and RNA binding is still DN. On the other hand, binding to Gle1 is essential, since changes that altered Dbp5’s interaction with Gle1 eliminated or reduced the R369G DN effect [dbp5-E323K/R369G, dbp5-E473K/R369G] [Fig. 4B]. The fact that R369G cannot bind RNA,
inhibits wild-type activity in vitro by limiting Gle1 [Fig.
5A,C], and is localized at the NE in nap159ΔN cells [Fig.
5E] provides evidence for RNA binding facilitating release
of Dbp5 from Gle1.

The human R372G mutant also had a negative effect on
mRNA export [Fig. 7A,B], resulting in poly(A)+ mRNA
accumulation in nuclear speckles. Using the mammalian
cell system for live-cell imaging, we directly monitored
individual mRNPs in cells expressing the DN hDbp5-
R372. Not surprisingly, expression of hDbp5-R372G in-
creases the level of mRNPs in nuclei and inhibits mRNA
export [Fig. 7]. Importantly, there is also a dramatic in-
crease (~10-fold) in the number of mRNPs located at the
nuclear periphery, most likely at NPCs, and these mRNPs
are transiently immobile.

To date, only one mRNA has been monitored at the
electron microscopy level for export directionality and
mRNP composition: The Balbiani ring mRNP from
Chironomus tentans passes through NPCs with its 5’
end leading [Mehlin et al. 1992]. However, it is not known
whether this is a general mechanism for mRNA export.
The mRNPs we analyzed are localized by visualizing the
YFP-MS2 protein bound to the 3’ UTR, and thus the 3’
end of the mRNP might still be nuclear, whereas the 5’
end might have entered the NPC channel and reached the
CFs. Overall, the mRNPs in the R372G cells are blocked
at a stage where their productive interaction with wild-
type Dbp5–Gle1 is required.

Although Dbp5 is abundant in the cytoplasm and is
readily detected at NPCs, Dbp5 undergoes nucleocytoplas-
ic shuttling [Hodge et al. 1999] and has both genetic and
physical interactions with the transcription machinery
[Eschuc et al. 2003]. Thus, it is possible that yeast
Dbp5 associates with mRNPs first in the nucleus and
accompanies them to and through the NPC, with Dbp5
associating with CFs at the time of remodeling. The only
reported case in which Dbp5 is detected associated with
nuclear mRNA/mRNP is the Balbiani ring mRNPs from
C. tentans [Zhao et al. 2002]. To date, there are no data
supporting an association between yeast Dbp5 and mRNPs
in the nucleus. Our finding here that R369G, which does
not bind mRNA, still localizes at NPCs demonstrates that
Dbp5 does not need to arrive at NPCs with an mRNP to
interact with Gle1. Moreover, because hDbp5’s binding
sites for RNA and Nup214 overlap [von Moeller et al.
2009], if Dbp5 is bound to an exiting mRNP, the initial
interaction at the NPC for Dbp5 is likely with Gle1, such
that Dbp5 does not disassociate from the mRNP before
remodeling is executed.

Combining the results from the in vivo and in vitro
studies presented here with findings obtained previously
(for review, see Stewart 2010) and in an accompanying
study [Noble et al. 2011] allows us to propose a detailed
model for the Dbp5 cycle at the NPC. We propose that
individual Dbp5 polypeptides go through multiple cycles
of ATP binding, ATP hydrolysis, and ADP release, along
with remodeling of mRNP, before being replaced by
another Dbp5. During this process, Dbp5 interacts alter-
nately with Nup159 and Gle1. The Nup159 interaction
serves to release ADP from those Dbp5 molecules that
have become ADP-bound by hydrolysis of ATP in
conjunction with mRNP remodeling [Noble et al. 2011],
and also facilitates its interaction with Gle1. It is not
known when during the cycle Dbp5 becomes bound to
ATP. As the intracellular concentration of ATP is high (>1
mM) [Ozalp et al. 2010], Dbp5 might bind ATP soon after
dissociation of ADP. However, because Gle1-IP6 promotes
ATP binding in vitro [Noble et al. 2011], Dbp5 might remain
in the apo form until it moves from Nup159 to Gle1. The
Dbp5–Nup159 interaction could facilitate the functionally
critical interaction between Dbp5 and Gle1-IP6, although
several experiments indicate that Dbp5 binding to Nup159
is not essential for export [Hodge et al. 1999; Weirich et
al. 2004; Noble et al. 2011]. Moreover, competition for Gle1 by
R369G does not require Nup159. Once bound to ATP and
Gle1-IP6, interaction with the mRNP is enabled and ATP
is hydrolyzed. This sequence of interactions, the
conformational change associated with the conversion of
Dbp5–ATP to Dbp5–ADP is harnessed to mediate mRNP
remodeling and the release of mRNA-bound proteins.
The entire process positions Dbp5 to hydrolyze ATP precisely at
the site where mRNPs exit the NPC for release into the
cytoplasm. Following this sequence of events, Dbp5–ADP
either enters another round of this cycle or dissociates. What
determines which of these happens might be stochastic, but
other factors could be involved. This model is developed
thoroughly in the accompanying study [Noble et al. 2011].

How many remodeling cycles a Dbp5 molecule goes
through on average before dissociating from the NPC is
not known. Two groups measured the time taken for
a reporter mRNP to be translocated through an NPC and
released into the cytoplasm, and found the time to be ~0.2
sec (Grunwald and Singer 2010) and <0.5 sec [Mor et al.
2010]. The transcripts examined by Mor et al. (2010) were
larger than those examined in the other study, and this
may explain the differences in transport times measured.
Whether mRNPs in yeast are transported with the same
kinetics is not known, but it is likely to be relatively
similar. Based on our FRAP experiments, Dbp5 spends, on
average, ~0.8 sec associated with NPCs, which is consist-
tent with one NPC-associated Dbp5 mediating a limited
number of mRNP remodeling events.

Although the role of Nup159 in this cycle is not
essential, ADP cannot be efficiently released from Dbp5
at NPCs without the Nup159-NTD [Noble et al. 2011],
and this might prevent a single Dbp5 molecule from partici-
pating in multiple enzymatic cycles at an NPC. Without
Nup159 binding, far fewer Dbp5 molecules would proceed
through another cycle. Consequently, in nup159ΔN cells,
lower binding sites on Gle1 might be occupied by Dbp5 at
any one time, explaining the dramatically reduced signal
for Dbp5-GFP at NPCs in nup159ΔN cells. In these cells,
ADP could possibly be released from Dbp5 through the
action of an as-yet- unidentified cytoplasmic Dbp5–ADP
exchange or release factor. Because Dbp5 and its activation
by Gle1-IP6 are also important for translation termination
[Gross et al. 2007; Bolger et al. 2008], it is highly likely that
there is another factor besides Nup159 that normally
mediates release of ADP from Dbp5–ADP generated
during translation termination. Other genetic experiments
support these conclusions. Overexpression of Dbp5 suppresses the nup159ΔN temperature-sensitive defects, possibly by providing sufficient Dbp5-ATP to permit normal mRNA export and growth in the absence of the ADP release activity of Nup159. As shown in the accompanying study (Noble et al. 2011), Dbp5-R256D/R259D has a greater ability to release ADP than does wild-type Dbp5, and therefore does not require Nup159’s NTD for ADP release.

Several important questions about the mechanism of mRNA export remain for future study. We do not know whether there is coordination among Dbp5s bound to multiple Nup159s at the same NPC. We do not know how many polypeptides are removed from a given mRNP during export, how long this process takes, and to what extent this is dependent on the length of the RNA. Although the data presented above are consistent with a single molecule of Dbp5 mediating the export of a single mRNP, more precise studies will be needed to address this definitively. These are challenging questions that are not amenable to in vitro studies. Therefore, answering them is likely to require advances in our ability to visualize the details of mRNA export and dissociation of protein from mRNP at the single-molecule level.

Materials and methods

Plasmids and yeast strains

Yeast strains and plasmids used are listed in Supplemental Tables S1 and S2. All strains were grown and media prepared using standard methods (Sambrook and Russell 2001). DBP5 point mutants were made using the QuikChange Site-Directed Mutagenesis kit (Stratagene no. 200519). Oligonucleotide sequences are listed in Supplemental Table S3. Growth assays were performed as described (Hodge et al. 2010). For growth assays comparing growth on dextrose plates versus galactose plates, cells were grown overnight in medium containing 2% raf prior to the growth assay.

Cell culture

HeLa cells were cultured in complete medium (DMEM; Invitrogen) supplemented with 10% FBS at 37°C in 5% CO2. Human U2OS cells stably expressing Mini-Dys-MS2 or Mini-Dys-MS2-intron (Mor et al. 2010) were maintained in low-glucose Dulbecco’s modified Eagle’s medium (DMEM) (Beit Haemek) containing 10% fetal bovine serum (FBS) (HyClone Laboratories). These cells were fixed and processed as described (Watkins et al. 1998) for hybridization in buffer containing 0.5 μg/μL tRNA, 0.5 μg/μL ssDNA, and 1 ng/μL Oligo-dT-Cy3.

Western blotting

Crude cell lysates were prepared by a method adapted from Yaffe and Schatz (1984). Briefly, cells were harvested, washed with water, lysed in 1.85 M sodium hydroxide and 7.4% β-mercaptoethanol, and incubated for 10 min on ice. An equal volume of 50% trichloroacetic acid was added and incubated for 10 min on ice, and precipitated protein was collected by centrifugation. Samples were washed with 500 μL of 1 M Tris base and resuspended in SDS sample buffer (Laemmli 1970). Equal amounts of protein from each extract were separated by electrophoresis on 10% Bio-Rad precast Tris-HCl polyacrylamide gels (Bio-Rad no. 161-1155). Dbp5 was visualized with an anti-Dbp5 Ab (D3M3S) raised against the Dbp5 NTD (Sny-Hodge et al. 1998) or anti-Gle1 raised against MBP-Gle1 (Bohler et al. 2008).

In vitro ATPase assays

ATP hydrolysis assays were conducted using an NAD+ enzyme-coupled absorbance assay as described previously (Alcazar-Roman et al. 2010). Briefly, standard ATPase reactions were assembled with Dbp5 or indicated variant in 10 mM HEPES [pH 7.5], 45 mM NaCl, 3 mM MgCl2, and 10% glycerol with, where indicated, Gle1, 100 nM IP6 (Sigma Chemical Co.), and oligo(A) 25-mer RNA in the presence of 1 mM ATP. Competition assays with R369G or K144Q, minus mutant protein alone from Vi for Dbp5 with Gle1-IP6, minus Dbp5 alone. The percent ATPase activation in competition and rescue assays was calculated by subtracting measured initial velocities (Vi) for ATP hydrolysis in the presence of R369G or K144Q, minus mutant protein alone from Vi for Dbp5 with Gle1-IP6, minus Dbp5 alone.
ATP, RNA, IP<sub>6</sub>, Gle1, and Nup159 in vitro binding assays

ATP binding was assessed as described (Solem et al. 2006). Briefly, 1 mM wild-type or variant Dbp5 was incubated with 1 mM α-32P-ATP (10 mCi/mmol) (MP Biomedicals) in 10 mM HEPES (pH 7.5), 45 mM NaCl, 3 mM MgCl<sub>2</sub>, and 10% glycerol for 10 min on ice. Oligo(A)25 RNA (Dharmacon), Gle1, and/or IP<sub>6</sub> were added to a final concentration of 2 μM, 1 μM, and 400 nM, respectively, as indicated. Cross-linking was conducted using a Stratalinker 1800 (Stratagene) for 10 min at 3 cm in BD Falcon UV transparent 96-well plates (no. 353261). Binding reactions were removed from the 96-well plates and incubated with excess, unlabeled ATP:MgCl<sub>2</sub> and 50 U of RNase I (Applied Biosystems) for 30 min at room temperature to reduce non-specific binding and cleave-bound RNA. Resulting samples were resolved by denaturing (SDS) gel electrophoresis. Bound ATP was detected by autoradiography. The percent ATP binding was calculated as the ATP-bound intensity versus a non-cross-linked sample as a background control. Gle1-IP<sub>6</sub>-induced increase in ATP binding was calculated as fold increase in signal intensity with or without Gle1-IP<sub>6</sub>. RNA binding (with AMP-PNP) was assayed by filter binding as described previously (Tran and Wente 2000), using a 5'-32P-labeled oligo(A)25 RNA. For Dbp5 interaction, soluble binding assays were conducted with bacterially expressed, recombinant Dbp5 and Nup159 proteins as described (Noble et al. 2011). Dbp5 enhancement of IP<sub>6</sub> binding by Gle1 was conducted using a PEG precipitation assay as described (Alcazar-Roman et al. 2006). Direct Gle1 binding to wild-type and R369G Dbp5 was conducted using an established soluble binding assay (Alcazar-Roman et al. 2010).

Acknowledgments

We thank members of the Cole, Wente, and Shaw-Tal laboratories for discussions. Support for this work was provided by grants from the NIH (GM33998 to C.N.C.; R37 GM51219 to S.R.W., 1F32 GM075459 to E.J.T.; 1F31 HD061181 to K.N.N.; and 1F31 NS070431 and 5T32 CA119925 to A.F.W.), the European Research Council (to Y.S.T.), and the Israel Science Foundation (grant 250/06 to Y.S.T.). J.J.S. was supported by a training grant from the NIH (AR07576). Y.S.T. is the Jane Stern Lebell Family Professor in Life Sciences at BIU.

References


Hodge CA, Colot HV, Stafford P, Cole CN. 1999. Rat8p/Dbp5p is a shuttling transport factor that interacts with Rat7p/Nup159p and Gle1p and suppresses the mRNA export defect of xpo1-I cells. EMBO J 18: 5778–5788.


GENES & DEVELOPMENT


